Radiolabeled cyclic peptides in precision oncology: Current advances and future perspectives
Radiolabeled peptides designed to find specific tumor markers enable precise cancer imaging and radiotherapy with fewer off-target effects.
This review covers radiolabeled cyclic peptides as vectors for next-generation radiopharmaceuticals in precision oncology, highlighting their structural advantages for tumor targeting. It discusses applications across multiple biomarker targets including FAP and PD-L1.
What the study was
- Study design
- Narrative review
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal of Controlled Release
Why it surfaced
Solid review of radiopharmaceutical theranostics in J Control Release. Incremental contribution.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.